Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Vaccinations

Cell-mediated Immune Responses

Cell-mediated Immune Responses

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence-Based Expert Review.

International forum of allergy & rhinology·2026

Same author

The Potential Role of a Whole Food Plant-Based Diet on Fibromyalgia Symptoms: A Review Article.

American journal of lifestyle medicine·2026

Same author

Challenges in accessing cancer care among ethnic cancer patients: A systematic review.

Patient education and counseling·2026

Same author

Rating the Efficacy of Diagnostic Imaging Studies Conducted for the Workup of Musculoskeletal Tumors.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2025

Same author

Determinants of persistence and recovery of chronic coronavirus disease 2019 chemosensory dysfunction.

The Journal of allergy and clinical immunology·2024

Same author

TCF1-LEF1 co-expression identifies a multipotent progenitor cell (T<sub>H</sub>2-MPP) across human allergic diseases.

Nature immunology·2024

Search research articles

Related Experiment Video

Updated: May 1, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Advances in subcutaneous immunotherapy.

Anna J Knisely¹, Stella Lee

¹Division of Sinonasal Disorders and Allergy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Current Opinion in Otolaryngology & Head and Neck Surgery

|March 29, 2014

Summary

This summary is machine-generated.

Advances in subcutaneous immunotherapy (SCIT) offer faster desensitization and improved safety for allergic disease treatment. Novel approaches target immune pathways for quicker tolerance and reduced side effects.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Experiment Videos

Last Updated: May 1, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Area of Science:

Immunology
Allergy Research
Therapeutic Development

Background:

Subcutaneous immunotherapy (SCIT) faces limitations in treatment duration and potential systemic side effects.
Allergic diseases represent a significant global health burden, necessitating improved therapeutic strategies.

Purpose of the Study:

To review recent advances in subcutaneous immunotherapy (SCIT) for allergic diseases.
To highlight novel approaches for more rapid desensitization and improved safety profiles.

Main Methods:

Review of emerging molecularly engineered compounds and delivery vehicles for allergen immunotherapy.
Analysis of targeted therapies focusing on B-cell and T-cell immune pathways.
Evaluation of combination strategies with immune modifiers and novel vaccine formulations.

Main Results:

Molecularly engineered compounds and delivery systems facilitate rapid and efficient desensitization.
Epitope-based compounds and hypoallergenic recombinant vaccines show potential for enhanced immunogenicity with reduced side effects.
Combination therapies with immune modifiers may further improve treatment outcomes.

Conclusions:

Advances in SCIT present new opportunities to enhance patient safety, efficacy, and compliance.
Epitope-based immunotherapy and carrier-fusion peptides can rapidly induce tolerance by selectively targeting B-cell and T-cell pathways.